Evidence map›Paper›PMID 40822287›Full record

ArticleThe Lancet regional health. Western Pacific2025

Evaluating the cost-effectiveness of levofloxacin therapy for household contacts of multidrug-resistant tuberculosis in Vietnam.

Tasnim Hasan, Nguyen Thu Anh, Nguyen Binh Hoa, Nguyen Viet Nhung, H Manisha Yapa, Stephen M Graham, Ben J Marais, Guy B Marks, Tom Lung, Greg J Fox

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Lancet regional health. Western Pacific, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Tasnim HasanNHMRC Clinical Trials Centre, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.
Nguyen Thu AnhThe University of Sydney Vietnam Institute, University of Sydney, Ho Chi Minh City, Vietnam.
Nguyen Binh HoaNational Lung Hospital, Hanoi, Vietnam.
Nguyen Viet NhungUniversity Medical Centre, Ho Chi Minh, Vietnam.
H Manisha YapaNHMRC Clinical Trials Centre, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.
Stephen M GrahamMelbourne Children's Global Health, University of Melbourne Department of Paediatrics and Murdoch Children's Research Institute, Royal Children's Hospital, Melbourne, Australia.
Ben J MaraisThe Sydney Infectious Diseases Institute (Sydney ID), The University of Sydney, Sydney, Australia.
Guy B MarksWoolcock Institute of Medical Research, Hanoi, Vietnam.
Tom LungSchool of Public Health, Faculty of Health and Medicine, University of Sydney, Sydney, Australia.
Greg J FoxNHMRC Clinical Trials Centre, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Multidrug-resistant tuberculosis (TB) threatens global TB control, on account of poor treatment outcomes, high treatment toxicity and costs. Recent trials demonstrated the effectiveness of six-months of levofloxacin (6Lfx) to prevent TB disease among high-risk contacts. However, the cost-effectiveness of this strategy has not previously been evaluated. Methods: The VQUIN study was a double-blinded randomised control trial in Vietnam assessing the effectiveness of 6Lfx in household contacts of multidrug resistant/rifampicin resistant TB (MDR/RR-TB) to prevent progression to TB disease. Incorporating in-trial costs and effectiveness outcomes from the VQUIN trial, we developed a closed cohort, decision-analytic Markov model to assess the cost effectiveness of 6Lfx versus placebo in a cohort exposed to MDR/RR-TB in Vietnam. Findings: Over a 20-year time horizon, the provision of 6Lfx preventative therapy to household contacts of people infected with MDR/RR-TB was found to gain a total of 40.1 QALYs per 1000 population and save US$23,145 per 1000 population, indicating the strategy was cost saving. MDR/RR-TB cases averted over 20 years was 19.9 per 1000 population treated with 6Lfx, and the number of deaths averted was 3.2 per 1000 people treated. Interpretation: 6Lfx therapy is a cost-saving strategy to reduce the incidence of active disease in household contacts of MDR/RR-TB in a resource-limited setting. Funding: National Health and Medical Research Council Project Grant (#1081443). GJF was supported by a NHMRC Leadership Fellowship (Level 1) (#2007920).

Indexed as

Cost-effectivenessDrug-resistant tuberculosisHousehold contactsLevofloxacin

Identifiers

PMID40822287
PMCPMC12355538

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.